US 12,313,632 B2
Tepoxalin targeting of ABCB1 overexpressing cancers
Steven Corsello, Boston, MA (US); Ryan Spangler, Cambridge, MA (US); Rohith Nagari, Cambridge, MA (US); and Todd Golub, Cambridge, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US); DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); and INSTITUTO CARLOS SLIM DE LA SALUD, A.C., Mexico City (MX)
Appl. No. 17/291,458
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); DANA-FARBER CANCER INSTITUTE, INC.; and INSTITUTO CARLOS SLIM DE LA SALUD, A.C., Mexico City (MX)
PCT Filed Nov. 8, 2019, PCT No. PCT/US2019/060516
§ 371(c)(1), (2) Date May 5, 2021,
PCT Pub. No. WO2020/097492, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/758,294, filed on Nov. 9, 2018.
Prior Publication US 2022/0065864 A1, Mar. 3, 2022
Int. Cl. C12Q 1/68 (2018.01); A61K 31/415 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07H 21/04 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)
CPC G01N 33/57492 (2013.01) [A61K 31/415 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70596 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method for treating a subject having cancer, the method comprising:
(a) identifying the presence in a sample of the subject of one or more of the following: (i) high ABCB1 mRNA expression levels, (ii) high ABCB1 protein expression levels and/or (iii) amplification of the ABCB1 locus, in the sample as compared to an appropriate control level; and
(b) administering tepoxalin to the subject; thereby treating the subject having cancer.